Dublin, Nov. 06, 2017 -- The "Biomarkers - Technologies, Markets and Companies" report from Jain PharmaBiotech has been added to Research and Markets' offering.
This report follows the broad definition of a biomarker as a characteristic that can be objectively measured and evaluated as an indicator of normal biological or pathogenic processes as well as pharmacological responses to a therapeutic intervention. Tests based on biomarkers have been around for more than half a century, but interest in their application for diagnostics and drug discovery as well as development has increased remarkably since the beginning of the 21st century. This report describes different types of biomarkers and their discovery using various -omics technologies such as proteomics and metabolomics. Molecular diagnostics technologies are used for the discovery of biomarkers and new tests are also based on biomarker.
Currently the most important applications of biomarkers are in drug discovery and development. The role of biomarkers in various therapeutic areas particularly cancer, cardiovascular diseases and disorders of the central nervous system, is described. Biomarkers are useful not only for diagnosis of some of these diseases but also for understanding the pathomechanism as well as a basis for development of therapeutics.
Biomarkers will facilitate the combination of therapeutics with diagnostics and will thus play an important role in the development of personalized medicine. Biomarkers play a role in use of pharmacogenetics, pharmacogenomics and pharmacoproteomics for development of personalized medicine.
Many of the regulatory issues concerning biomarkers are related to genomics, proteomics, molecular diagnostics and pharmacogenomics/pharmacogenetics. Validation of biomarkers and their role in clinical trials is discussed.
Biomarker markets are estimated from 2016 to 2026 according to share of markets for various technologies and applications: proteomics, metabolomics, molecular diagnostics, drug discovery, clinical trials, and bioinformatics. Market values are further split according to therapeutic applications and major geographical areas. Unfulfilled needs in biomarkers are identified as well as the drivers for biomarker markets. Challenges facing the biomarker industry and strategies for developing biomarker markets are discussed.
A large number of companies with varying technical backgrounds are involved in biomarkers and 302 of these are profiled in part 2 of the report with classification into various categories.These also include major pharmaceutical companies. There is tabulation of 466 collaborations between companies and additional academic collaborations are mentioned in the individual profiles of companies. The report is supplemented by 910 references, 80 tables and 22 figures.
Key Topics Covered:
Part 1: Technologies & Applications
Executive Summary
1. Introduction
2. Technologies for Discovery of Biomarkers
3. Biomarkers and Molecular Diagnostics
4. Biomarkers for Drug Discovery & Development
5. Role of Biomarkers in Healthcare
6. Biomarkers in Metabolic Disorders
7. Biomarkers in Immune Disorders
8. Biomarkers of Musculoskeletal Disorders
9. Biomarkers of Infectious Diseases
10. Biomarkers of Genetic Disorders
11. Biomarkers of Aging
12. Nutritional Biomarkers
13. Biomarkers of Cancer
14. Biomarkers of Disorders of the Nervous System
15. Biomarkers of Cardiovascular Disorders
16. Biomarkers of Pulmonary Diseases
17. Biomarkers in Gynecology and Obstetrics
18. Biomarkers & Personalized Medicine
19. Biomarkers and Regulatory issues
20. References
Part II: Markets & Companies
21. Markets for Biomarkers
22. Companies
For more information about this report visit https://www.researchandmarkets.com/research/h42n86/biomarkers
CONTACT: Research and Markets
Laura Wood, Senior Manager
[email protected]
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics: Biomarkers


Russia Moves to Fully Block WhatsApp as Kremlin Pushes State-Backed MAX App
Spirit Airlines Seeks Court Approval to Auction 20 Airbus A320/A321 Aircraft Amid Bankruptcy
Gates Foundation Denies Financial Ties to Jeffrey Epstein Following DOJ Email Release
Senators Urge CFIUS Review of UAE Investment in Trump-Linked Crypto Firm World Liberty Financial
Valero Energy Expands Venezuelan Crude Imports as U.S. Sanctions Ease
ANZ Shares Hit Record High After Strong Q1 Profit and Cost-Cutting Gains
Xiaomi EV Deliveries Surpass 600,000 Units as SU7 and YU7 Drive Strong Growth
GE Aerospace Expands Singapore Engine Repair Hub with Automation and AI to Tackle Aviation Bottlenecks
Grok AI Market Share Surges as xAI Faces Scrutiny Over Image Generation Controversy
Vale Reports $3.8 Billion Q4 Net Loss Amid Nickel Asset Impairment and Samarco Provisions
Sachem Head Boosts Warner Bros. Discovery Stake Amid Netflix Deal and Paramount Bid
Novocure Stock Surges 30% After FDA Approves Optune Pax for Pancreatic Cancer Treatment
AbbVie Sues HHS Over Medicare Price Controls on Botox Under Inflation Reduction Act
Michael Kors Marks 45 Years at New York Fashion Week with Fall/Winter Collection Showcase
Bank of America CEO Brian Moynihan’s 2025 Compensation Rises 17% to $41 Million Amid Strong Profit Growth
U.S. Commerce Department Reaches $252 Million Settlement With Applied Materials Over China Exports 



